Day One Biopharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia from Needham maintained a Buy rating on the stock and has a $16.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ami Fadia has given her Buy rating due to a combination of factors influencing Day One Biopharmaceuticals’ current and future performance. Despite the company’s second-quarter earnings per share being slightly better than expected, driven by reduced research and development and selling, general, and administrative expenses, Ojemda’s sales were slightly below consensus expectations. However, the sales were bolstered by increased market adoption and new patient prescriptions, particularly in the latter part of the quarter, supported by promising FIREFLY-1 study data.
Looking ahead, while the full-year 2025 revenue guidance for Ojemda was lower than market expectations, the analyst anticipates potential upside from upcoming data releases, such as the three-year follow-up from the FIREFLY-1 study expected in the fourth quarter of 2025. This future data could provide a catalyst for the stock, justifying the Buy rating despite the current underwhelming guidance. The analyst’s price target has been adjusted to reflect these dynamics, but the long-term outlook remains positive.
In another report released today, JonesTrading also maintained a Buy rating on the stock with a $26.00 price target.